Corticosteroids in patients with community-acquired pneumonia
Date First Published:
August 27, 2026
Last Updated:
August 27, 2026
Report by:
Bradley Burns DO, Nathanial Ladaga DO, Senior EM Resident, EM faculty (Corewell Health/Michigan State University EM Residency Program, Grand Rapids MI)
Search checked by:
Jeffrey S. Jones MD, Research Director
Three-Part Question:
In [adult ED patients with community acquired pneumonia] does [adjunctive systemic corticosteroid therapy compared with standard antibiotic therapy alone] [improve clinically relevant outcomes such as mortality, need for mechanical ventilation, ICU admission, time to clinical stability, or adverse events]?
Clinical Scenario:
A 62-year-old man presents to the ED with fever, productive cough, tachypnea, and hypoxia. His chest X-ray shows right lower lobe consolidation, and his CURB-65 score is 3, indicating severe community-acquired pneumonia. Despite appropriate antibiotics and fluids, he remains hypotensive and requires escalating oxygen support. The ED team wonders whether adding systemic corticosteroids could improve outcomes or reduce the likelihood of ICU admission.
Search Strategy:
Medline 1966-07/2026 using PubMed, Cochrane Library (2026), and Embase
Search Details:
[Community-acquired pneumonia AND (Adrenal Cortex Hormones /administration & dosage]. Limit to meta-analysis, adults
Outcome:
36 articles were found; 4 recent meta-analyses answered the clinical question.
Relevant Paper(s):
| Study Title | Patient Group | Study type (level of evidence) | Outcomes | Key results | Study Weaknesses |
|---|---|---|---|---|---|
| Low-dose corticosteroids in severe pulmonary infection: a meta-analysis of randomised controlled trials Lac J, Han S, Ahmad M, Starey H, Ganguly S, Tett M, Adeyemi O, Bray JJH, Ahmad MT, Providência R. 2026 July London, UK | Twelve RCTs including 4622 adults with severe pulmonary infections | Systematic review and meta-analysis comparing low-dose corticosteroids (≤400 mg hydrocortisone-equivalent daily) to placebo or standard care . | short-term mortality (≤90 days). Secondary outcomes included 28-day mortality, 30-day mortality, number of patients with at least one serious adverse event, length of hospital stay and ICU stay | The pooled OR showed a short-term mortality benefit: 0.83, number needed to treat: 37.8. There was a reduction in length of ICU stay in patients with CAP, with a pooled mean difference of –0.78 days. The use of corticosteroids did not significantly affect the length of hospital stay or severe adverse events. Longer courses (>7 days) were associated with greater mortality reduction than shorter courses (≤7 days). | The differences in the definition of ‘severe’ pulmonary infections may complicate the interpretation of pooled effects. Additionally, the lack of data on timings between hospital admission and initiation of the corticosteroid regimen adds another confounding variable. |
| Corticosteroids for adult patients hospitalised with non-viral community-acquired pneumonia: a systematic review and meta-analysis Pitre T, Pauley E, Chaudhuri D, et al. 2025 May Canada, UK, Australia, USA, and Spain | 30 eligible RCTs, including a total of 7519 adult patients with suspected or probable CAP. | Systematic review and meta-analysis | Short-term (28–30 days) and long-term (60–90 days) mortality; need for invasive mechanical ventilation (IMV); duration of ICU stay; hospital stay; hyperglycemia requiring intervention ; and incidence of secondary infections. | Corticosteroids probably reduced short-term mortality (RR 0.82) while the reduction in longer term mortality is less certain (RR 0.89). Corticosteroids reduced the need for IMV (RR 0.63) and may reduce duration of ICU stay (1.53 days fewer) and hospital stay (MD 2.30 days fewer). Corticosteroids probably increased hyperglycaemia requiring intervention (RR 1.32) but probably have no effect on secondary infections (RR 0.97). | Heterogeneity in terms of RCTs spanning seven decades, where usual care has changed, and outcomes from CAP have improved. Eligibility criteria differed between RCTs, as did the doses and steroid drugs tested. Not all investigators provided data for analysis, resulting in a small number of sepsis and ARDS trials. There was marked variation in defining ‘severe’ CAP across the included studies. |
| Comparative effect of different corticosteroids in severe community-acquired pneumonia: a network meta-analysis Zhu L, Zeng J, Li H, Li K, Chen X. Comparative effect of different corticosteroids in severe community-acquired pneumonia: a network meta-analysis. 2025 April China | 11 studies, involving 2042 adult participants with severe CAP | Systematic review and meta-analysis | All-cause mortality, secondary efficacy outcome was mechanical ventilation (MV), and safety outcome was the incidence of serious adverse events (SAEs). | Among the four corticosteroids, only hydrocortisone was significantly more effective at reducing mortality than placebo (RR, 0.35). Additionally, hydrocortisone reduced the need for MV (RR, 0.73). Subgroup analysis indicated that low-to-moderate doses, short-course corticosteroids are associated with a reduction in both mortality and the need for MV. | The included RCTs varied in their diagnostic criteria for severe CAP and in their definitions and reporting of SAEs, which may have contributed to heterogeneity among the studies. None of the included studies in our meta-analysis provided specific data on the incidence of antibiotic-resistant pathogens or secondary bacterial or fungal infections. The generalizability of the findings may be limited by heterogeneity across study populations. |
| Glucocorticoids can reduce mortality in patients with severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials Gu X, Yang P, Yu L, Yuan J, Zhang Y, Yuan Z, Chen L, Zhang X, Chen Q. 2025 March China | 8 studies involving 1769 adult patients with severe community-acquired pneumonia | Systematic review and meta-analysis | in-hospital mortality, mechanical ventilation duration, gastrointestinal bleeding, secondary infection, and other outcome measures between the glucocorticoid group and the control group. | Hospital mortality in the glucocorticoid group was significantly lower than that in the control group [8 studies, RR 0.59]. The duration of mechanical ventilation in the glucocorticoid group was significantly shorter than that in the control group [Mean Difference (MD) −3.08]. There was no significant difference in the incidence of gastrointestinal bleeding (RR 0.94) or secondary infection (RR 0.85) between the glucocorticoid group and the control group. In subgroup analysis, mortality was significantly lower in the hydrocortisone group compared to the control group (6.3% vs. 14.6%, p < 0.01). | The optimal type, dosage, and duration of glucocorticoids have not been determined. Due to the unavailability of data on shock patients in this study, the authors were unable to conduct a subgroup analysis for patients with or without shock. Finally, the use of glucocorticoids may yield different outcomes for community-acquired pneumonia caused by different pathogens. |
Author Commentary:
Community acquired pneumonia remains one of the most common and deadly infections treated in the ED, especially in older adults and those with severe disease. Steroids are inexpensive, widely available, and biologically plausible as a therapy to blunt the inflammatory cascade that drives respiratory failure. However, they also carry meaningful risks—hyperglycemia, delirium, and potential secondary infection—making indiscriminate use potentially harmful. Understanding which CAP patients truly benefit helps ED clinicians make targeted, evidence based decisions rather than reflexively adding steroids. Steroids reliably shorten recovery and hospital stay but increase metabolic and infectious complications, and may worsen some long term outcomes.
Bottom Line:
In adults presenting to the ED with community acquired pneumonia, adjunctive corticosteroids should not be used routinely, but they may provide meaningful benefit—including reduced mortality and need for ventilation—in severe CAP or impending critical illness.
Level of Evidence:
Level 1: Recent well-done systematic review was considered or a study of high quality is available
References:
- Lac J, Han S, Ahmad M, Starey H, Ganguly S, Tett M, Adeyemi O, Bray JJH, Ahmad MT, Providência R.. Low-dose corticosteroids in severe pulmonary infection: a meta-analysis of randomised controlled trials
- Pitre T, Pauley E, Chaudhuri D, et al.. Corticosteroids for adult patients hospitalised with non-viral community-acquired pneumonia: a systematic review and meta-analysis
- Zhu L, Zeng J, Li H, Li K, Chen X. Comparative effect of different corticosteroids in severe community-acquired pneumonia: a network meta-analysis.. Comparative effect of different corticosteroids in severe community-acquired pneumonia: a network meta-analysis
- Gu X, Yang P, Yu L, Yuan J, Zhang Y, Yuan Z, Chen L, Zhang X, Chen Q.. Glucocorticoids can reduce mortality in patients with severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials